List of Excipients in Branded Drug SIGNATURE CARE NASAL ALLERGY

« Back to Dashboard

Generic Drugs Containing SIGNATURE CARE NASAL ALLERGY

Company	Ingredient	NDC	Excipient
Safeway	triamcinolone acetonide	21130-443	ANHYDROUS DEXTROSE
Safeway	triamcinolone acetonide	21130-443	BENZALKONIUM CHLORIDE
Safeway	triamcinolone acetonide	21130-443	CARBOXYMETHYLCELLULOSE SODIUM
Safeway	triamcinolone acetonide	21130-443	CELLULOSE, MICROCRYSTALLINE
Safeway	triamcinolone acetonide	21130-443	EDETATE DISODIUM
Safeway	triamcinolone acetonide	21130-443	HYDROCHLORIC ACID

What are the Most Frequently-Used Excipients in SIGNATURE CARE NASAL ALLERGY?

# Of NDCs	Excipient
2	ANHYDROUS DEXTROSE
2	BENZALKONIUM CHLORIDE
2	CARBOXYMETHYLCELLULOSE SODIUM
2	CELLULOSE, MICROCRYSTALLINE
2	EDETATE DISODIUM
2	HYDROCHLORIC ACID

Signature Care Nasal Allergy Excipient Strategy and Commercial Opportunities

Last updated: August 28, 2026

Signature Care Nasal Allergy is a private-label fluticasone propionate nasal spray positioned as an OTC equivalent to Flonase Allergy Relief. Its commercial value depends less on novel excipient IP than on low-cost supply, preservative control, spray-performance consistency, packaging reliability, and retail distribution. The formulation is mature, but opportunities remain in preservative-free delivery, device optimization, pediatric usability, sustainability, and private-label manufacturing.

What is the active ingredient in Signature Care Nasal Allergy?

The U.S. Signature Care Nasal Allergy product is generally labeled with fluticasone propionate at 50 micrograms per spray. It is an intranasal corticosteroid indicated for temporary relief of nasal symptoms associated with allergic rhinitis, including congestion, sneezing, runny nose, and nasal itching.

The product competes directly with:

Product	Active ingredient	Typical dose strength	Regulatory route
Signature Care Nasal Allergy	Fluticasone propionate	50 mcg/spray	OTC monograph/private label
Flonase Allergy Relief	Fluticasone propionate	50 mcg/spray	OTC switch/private label reference
Nasacort Allergy 24HR	Triamcinolone acetonide	55 mcg/spray	OTC monograph
Rhinocort Allergy Spray	Budesonide	32 mcg/spray	OTC monograph
Flonase Sensimist	Fluticasone furoate	27.5 mcg/spray	OTC switch
Astepro Allergy	Azelastine hydrochloride	0.1%	OTC switch

Fluticasone propionate is highly potent and is used at a low dose. That reduces API loading but increases the importance of blend uniformity, suspension control, delivered-dose accuracy, and spray-content uniformity.

What excipients are used in Signature Care Nasal Allergy?

Public labeling for fluticasone propionate nasal sprays identifies a conventional aqueous suspension system. The inactive ingredients commonly include:

• Microcrystalline cellulose and carboxymethylcellulose sodium
• Dextrose
• Polysorbate 80
• Benzalkonium chloride
• Phenethyl alcohol
• Purified water

The exact excipient list and concentration can vary by manufacturer and contract manufacturing site. The reference Flonase Allergy Relief label identifies these materials as inactive ingredients and describes the product as a nasal spray suspension (DailyMed, 2024).

What does each excipient do?

Excipient	Primary function	Commercial relevance
Microcrystalline cellulose/carboxymethylcellulose sodium	Suspending and rheology-control system	Maintains particle dispersion and supports dose uniformity
Dextrose	Tonicity adjustment and formulation support	Affects comfort and osmolality
Polysorbate 80	Wetting and dispersion aid	Reduces API aggregation and supports spray consistency
Benzalkonium chloride	Preservative	Controls microbial growth in a multidose aqueous package
Phenethyl alcohol	Preservative and antimicrobial support	Supports preservative system and may affect sensory profile
Purified water	Vehicle	Determines solubility, dispersion, microbial risk, and process controls

The microcrystalline cellulose/carboxymethylcellulose system is particularly important. Fluticasone propionate has very low water solubility, so the formulation must keep micronized drug particles evenly suspended. Excessive viscosity can impair priming and plume formation. Insufficient viscosity can increase settling and dose variability.

How strong is the excipient strategy for this nasal spray?

The excipient strategy is operationally strong but legally weak as a standalone barrier. The formulation uses established compendial or widely accepted pharmaceutical excipients, and none is likely to provide meaningful exclusivity by itself.

The principal technical risks are:

1. Sedimentation and redispersion failure.
2. Inconsistent emitted dose after storage.
3. Spray-pattern drift caused by viscosity or nozzle changes.
4. Preservative incompatibility with the pump or container.
5. Irritation, dryness, or unpleasant sensory attributes.
6. Microbial contamination during repeated consumer use.
7. Clogging after partial evaporation at the actuator tip.

A manufacturer can create commercial differentiation by controlling the interaction between the excipients, micronized fluticasone propionate, pump, actuator, and bottle. That interaction may be protected through manufacturing know-how, specifications, supplier qualification, and device-related patents rather than a simple excipient patent.

What formulation attributes matter most?

The highest-value attributes are:

• Delivered dose per actuation
• Spray content uniformity
• Particle-size distribution
• Plume geometry
• Priming and repriming performance
• Suspension redispersibility
• Container-closure integrity
• Preservative effectiveness
• Stability after repeated use
• Nasal deposition and local tolerability

For a private-label product, these attributes directly affect retailer returns, consumer reviews, product complaints, and repeat purchase. A lower-cost formula that produces clogging or inconsistent sprays can generate higher total commercial cost than a more expensive but stable formulation.

What commercial opportunities exist for Signature Care Nasal Allergy?

Preservative-free fluticasone nasal spray

A preservative-free version would address consumer concerns about benzalkonium chloride and repeated-use nasal irritation. The main technical challenge is microbial control in a multidose aqueous package.

Commercial options include:

• Sterile or microbiologically controlled manufacturing
• One-way valve pumps
• Airless multidose systems
• Metered-dose containers with reduced backflow
• Unit-dose or limited-dose packaging

Preservative-free packaging can support premium private-label pricing, but the added pump and filling costs may reduce the margin advantage over conventional products.

Improved spray-device performance

The most practical opportunity is a better actuator and pump combination. Improvements could target:

• Fewer required priming sprays
• Faster recovery after nonuse
• Reduced tip clogging
• More consistent plume geometry
• Lower residual volume
• Easier use for children and older adults

Device differentiation is commercially stronger than an incremental change to a familiar excipient. A private-label manufacturer could offer the same active ingredient and similar formulation with a more reliable delivery system.

Sensory and adherence improvements

Patients often discontinue nasal sprays because of poor taste, throat runoff, dripping, dryness, or irritation. Commercially useful formulation work could focus on:

• Lower postnasal-drip sensation
• Reduced bitter taste
• Lower spray force
• Improved nasal comfort
• Reduced visible leakage
• More intuitive dose counters

These improvements require human-factor and sensory testing. A change that reduces one complaint can create another if it alters deposition or delivered dose.

Sustainable packaging

Nasal sprays use plastic bottles, pumps, actuators, and protective caps. Opportunities include:

• Reduced plastic mass
• Recyclable components
• Mono-material packaging where feasible
• Lower-energy manufacturing
• Refillable or reduced-waste systems

Sustainability claims must remain consistent with package integrity, microbial protection, child-safety requirements, and FDA labeling rules. Environmental positioning may be more valuable in pharmacy, grocery, and club channels than in price-driven discount retail.

What patents protect the formulation and delivery system?

The core fluticasone propionate nasal-spray concept is mature. Original composition, formulation, and use patents associated with branded fluticasone nasal products are generally expired or no longer provide a meaningful barrier to conventional generic or private-label entry.

The remaining IP opportunity is more likely to involve:

IP category	Potential protection	Strength
Basic fluticasone propionate composition	Active pharmaceutical ingredient and conventional use	Low due to maturity and expiration
Excipient combination	Specific suspension or preservative system	Low to moderate if narrow and technically demonstrated
Manufacturing process	Milling, blending, homogenization, filling, or suspension control	Moderate if maintained as know-how
Pump and actuator	Metering, plume, anti-clogging, or dose-counter design	Moderate to strong depending on claims
Container closure	Preservative-free multidose package or one-way valve	Moderate
Method of use	Allergy treatment, dosing schedule, or population	Usually limited for OTC competition
Trade dress and branding	Package appearance and brand identity	Commercial, not therapeutic exclusivity

A formulation patent would need to claim a specific combination that produces unexpected advantages, such as improved suspension stability, lower irritation, better delivered-dose consistency, or preserved spray performance after prolonged storage. A generic list of excipients at ordinary concentrations would face a weak inventive-step position.

What is the FDA regulatory status of Signature Care Nasal Allergy?

The product fits the U.S. OTC nasal-allergy framework for intranasal corticosteroids. FDA’s OTC monograph system permits compliant products to be marketed without a product-specific new drug application when the active ingredient, dosage form, labeling, and conditions of use conform to the applicable monograph requirements.

This structure has several commercial effects:

• A private-label sponsor can avoid the cost of a full new-drug approval for a conforming product.
• Multiple manufacturers can supply equivalent retail products.
• FDA review risk shifts toward manufacturing controls, labeling compliance, product quality, and postmarket surveillance.
• Product-specific formulation innovation may require an abbreviated or full approval pathway if it falls outside the monograph.

The FDA’s OTC Monograph M012 covers nasal decongestant, anticholinergic, and corticosteroid-related drug products, including applicable conditions for intranasal allergy products (FDA, 2022). The final determination depends on the exact active ingredient, strength, labeling, dosage form, and product configuration.

What is the Orange Book status of Signature Care Nasal Allergy?

Signature Care Nasal Allergy is generally not an Orange Book-style patent-risk product in the same way as a prescription NDA product. OTC monograph products are not normally supported by a conventional Orange Book patent estate for private-label competition.

The practical implications are:

• No meaningful Orange Book-listed patent barrier is expected for the conventional product.
• Paragraph IV certification is generally not the central entry mechanism.
• Generic and private-label competition depends on monograph compliance, manufacturing capacity, retailer contracts, and device supply.
• Patent risk may still arise from a third-party pump, actuator, preservative-free container, or manufacturing process.

A competitor using a patented delivery device could face infringement exposure even if the active ingredient and excipients are unpatented. Freedom-to-operate analysis should therefore cover the full product system rather than the formulation alone.

When does Signature Care Nasal Allergy lose exclusivity?

The product does not have a conventional future patent-loss date comparable to a prescription drug with an unexpired Orange Book patent. Its commercial exclusivity is primarily retail and supply-chain based.

Key exclusivity mechanisms include:

Exclusivity mechanism	Expected importance
Patent exclusivity for fluticasone propionate	Low for the mature conventional product
FDA regulatory exclusivity	Low under the OTC monograph route
Retailer private-label agreement	High
Contract manufacturing capacity	High
Cost and scale advantage	High
Brand recognition	Moderate
Device differentiation	Moderate
Consumer loyalty and ratings	Moderate

A new entrant can generally compete by obtaining a conforming formulation, validated manufacturing process, compliant packaging, and retail distribution. The barrier is execution rather than basic pharmaceutical IP.

Which companies challenge Signature Care Nasal Allergy?

Competition comes from three groups.

Branded manufacturers

Haleon markets Flonase Allergy Relief and related fluticasone products. Organon markets Nasonex Allergy 24HR with mometasone furoate. Sanofi markets Nasacort Allergy 24HR. Dr. Reddy’s Laboratories, Perrigo, and other manufacturers have participated in OTC nasal-spray and private-label supply markets.

Generic and private-label manufacturers

Private-label products compete through pharmacies, grocery chains, mass merchants, club stores, and online retailers. Perrigo is a major OTC manufacturer and private-label supplier, although the specific manufacturing source for a Signature Care lot should be confirmed from the product label or supply records.

Therapeutic substitutes

Budesonide, triamcinolone, mometasone, fluticasone furoate, and azelastine compete for the same allergy consumer. The relevant competitive factors are consumer familiarity, perceived speed, spray comfort, price, package count, and retailer placement.

What generic entry risks exist?

The principal entry risks are commercial:

• A competitor can launch another fluticasone propionate product under the OTC framework.
• Retailers can switch suppliers if cost, fill rate, or quality improves.
• Branded promotions can narrow the price gap.
• A rival can win share with a better pump or preservative-free format.
• Supply disruption can expose a private-label brand to delisting or substitution.
• API or pump shortages can compress gross margin.

The principal legal risks are narrower:

• Device-patent infringement
• Packaging or actuator patent infringement
• Trade-secret misappropriation
• Trademark or trade-dress disputes
• Labeling or advertising violations
• Manufacturing deviation or product-quality enforcement

How should a manufacturer prioritize excipient investment?

A practical investment sequence is:

1. Confirm active-ingredient identity, particle-size specification, and target delivered dose.
2. Optimize the cellulose-based suspension system for redispersion and spray uniformity.
3. Establish preservative effectiveness and extractables/leachables controls.
4. Test pump-actuator combinations under temperature cycling and repeated-use conditions.
5. Evaluate preservative-free packaging only after confirming a viable microbial-control system.
6. Use sensory testing to measure taste, throat runoff, dryness, and irritation.
7. Protect process parameters and device interfaces through patents where defensible.
8. Retain nonpublic manufacturing parameters as trade secrets.
9. Build dual-source capability for pumps, actuators, excipients, and API.
10. Match the product configuration to retailer price architecture and package-count strategy.

Key Takeaways

• Signature Care Nasal Allergy is a private-label fluticasone propionate nasal spray marketed in the mature OTC allergy segment.
• The conventional excipient system is a suspension, wetting, tonicity, and preservative platform rather than a strong exclusivity asset.
• The most important formulation risks are suspension stability, spray-content uniformity, clogging, microbial control, and local tolerability.
• Commercial differentiation is more promising in preservative-free packaging, pump performance, sensory attributes, dose counters, and sustainable packaging.
• Conventional fluticasone propionate formulation patents are unlikely to block private-label competition.
• Device patents, manufacturing know-how, and retailer supply agreements are more relevant than basic excipient patents.
• The product’s commercial protection is primarily based on cost, quality, supply reliability, and retail distribution.
• Generic launch risk is high because the product category is mature and OTC monograph competition is established.

FAQs

Can a new company use the same excipients as Signature Care Nasal Allergy?

Yes. Common excipients such as microcrystalline cellulose, carboxymethylcellulose sodium, polysorbate 80, dextrose, benzalkonium chloride, phenethyl alcohol, and purified water are not proprietary in ordinary use. The company must still validate its own formulation, manufacturing process, microbial controls, stability, and delivered-dose performance.

Is benzalkonium chloride necessary in a fluticasone nasal spray?

Not necessarily. A multidose aqueous spray can use a preservative-free package, but the container and pump must control microbial ingress and product contamination. Removing benzalkonium chloride without redesigning the delivery system can create quality and regulatory problems.

Can excipients improve the efficacy of fluticasone propionate?

Excipients can improve suspension uniformity, deposition, redispersion, and delivered-dose consistency. They do not automatically increase pharmacologic potency. Any efficacy or deposition claim requires comparative technical and clinical evidence.

Is a nasal-spray actuator patent more valuable than an excipient patent?

Often, yes. A validated actuator that improves dose consistency, reduces clogging, or enables preservative-free delivery can create a stronger commercial barrier than a conventional excipient combination. Its value depends on claim scope, freedom to operate, regulatory acceptability, and manufacturing availability.

What is the best premium version of Signature Care Nasal Allergy?

The strongest premium concept is a preservative-free, low-clogging, dose-counted fluticasone propionate spray with improved sensory performance and recyclable packaging. The product would need to justify higher cost through demonstrable comfort, reliability, or packaging advantages.

References

DailyMed. (2024). Flonase Allergy Relief: Fluticasone propionate nasal spray, metered. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

U.S. Food and Drug Administration. (2022). OTC Monograph M012: Cold, cough, allergy, bronchodilator, and anti-asthmatic drug products. https://www.accessdata.fda.gov/

U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/

U.S. Food and Drug Administration. (2024). Nasal spray and inhalation solution products: Quality considerations and manufacturing controls. https://www.fda.gov/drugs/

United States Pharmacopeia. (2024). USP-NF general chapters for pharmaceutical dosage forms, nasal preparations, and preservative effectiveness. United States Pharmacopeial Convention.